In Search of Beautiful Molecules: A Perspective on Generative Modeling for Drug Design.

Area of Science:

• Artificial Intelligence in Drug Discovery
• Computational Chemistry
• Medicinal Chemistry

Background:

• Generative artificial intelligence (GenAI) shows promise for discovering novel drugs by exploring chemical space and designing molecules with desired properties.
• Despite advancements, GenAI's value in prospective drug discovery remains undemonstrated, highlighting a gap between potential and application.

Purpose of the Study:

• To define the criteria for successful Generative AI for Drug Discovery (GADD), focusing on generating "beautiful" molecules aligned with therapeutic objectives.
• To emphasize the critical role of human expertise and feedback in guiding AI models toward clinically relevant drug candidates.

Main Methods:

• Focus on five key considerations for GADD: chemical synthesizability, ADMET properties, target-specific binding, multiparameter optimization (MPO) functions, and human feedback.
• Propose Reinforcement Learning with Human Feedback (RLHF) as a method to align GenAI outputs with expert judgment, analogous to its use in large language models.

Main Results:

• The "beauty" of a molecule is context-dependent and requires nuanced judgment, making expert human input indispensable.
• While MPO frameworks aid optimization, they cannot fully replace the experience of drug hunters.
• RLHF is essential for shaping GenAI behavior towards therapeutically aligned molecules.

Conclusions:

• Successful GADD requires moving beyond generating novel molecules to creating "beautiful" ones that offer value beyond traditional methods.
• Future progress in GADD depends on improved property prediction, explainable AI systems, and the integration of human feedback loops.
• Ultimately, the success of AI-generated drug candidates is judged by experienced drug hunters and clinical outcomes.